CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c

CymaBay Therapeutics (NASDAQ: CBAY) reported Q3 EPS of ($0.32), $0.03 worse than the analyst estimate of ($0.29).

For earnings history and earnings-related data on CymaBay Therapeutics (CBAY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Xylem names Andrea van der Berg as CFO, effective Sept. 2026
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss